Health

STAT+: After a cancer vaccine’s first success, the race is on to expand the impact

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 25/10/2026, 08:36:25 UTC.

Briefings

A cancer vaccine trial presented at the European Society for Medical Oncology meeting showed a customized mRNA treatment reduced recurrence or death risk by 42% when combined with Keytruda for melanoma patients. James Larkin of London's Royal Marsden Hospital led the discussion on future deployment, while Vinod Balachandran of Memorial Sloan Kettering noted the long history of vaccine failures. The study was conducted by Merck and Moderna.

Key points

• A customized mRNA-based cancer vaccine reduced the risk of recurrence or death by 42% when combined with Keytruda in a trial presented at the European Society for Medical Oncology meeting.
• James Larkin of London's Royal Marsden Hospital and Vinod Balachandran of Memorial Sloan Kettering Cancer Center discussed the potential for expanding this treatment beyond melanoma.

Context

The study was presented at the European Society for Medical Oncology meeting in Madrid, where James Larkin of London's Royal Marsden Hospital and Vinod Balachandran of Memorial Sloan Kettering Cancer Center discussed the potential for expanding this treatment beyond melanoma. The trial was conducted by Merck and Moderna.

Limitations

The evidence is limited to a single trial presentation at a specific meeting in Madrid. The study is unverified and preprint status is not confirmed. The 42% reduction is based on a single trial and may not reflect broader clinical outcomes. The study was conducted by Merck and Moderna.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 25/10/2026, 08:44:34 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeigkxcc6er2nzdhkahzb6jr4yjezujjojteycmj55ro2g4kqyusure